

# INVITATION

TO THE 1<sup>ST</sup> SYMPOSIUM ON MINIMAL RESIDUAL DISEASE, NORDIC COUNTRIES

## Minimal residual disease in hematological malignancies: How deep is your response?

✔ Please see the full Agenda on page 2 for details.

**Date and time:** March 16<sup>th</sup>, 2017, 11.30-19.00

**Venue:** Park Inn by Radisson, Oslo Lufthavn, Henrik Ibsens veg, 2060 Gardermoen, Norway

[LINK TO MAP](#)

We are happy to extend an invitation to healthcare personnel with an interest in chronic lymphocytic leukemia and other hematological malignancies to a seminar on minimal residual disease (MRD) at Gardermoen in Norway.

To register for this meeting, send an email to [elisabeth.leirvik@abbvie.com](mailto:elisabeth.leirvik@abbvie.com) or [hanne.melaas@roche.com](mailto:hanne.melaas@roche.com) with your name, hospital and country. Please also specify whether you will be attending dinner or have any allergies. Deadline for signing up is March 8<sup>th</sup>.

AbbVie and Roche cover meeting costs in accordance with regulations.

Participants must arrange and cover transportation and accommodation themselves.

Upon registration for this meeting, you confirm that you follow rules and regulations valid in your work place and have obtained permission from your employer.


Best regards,

for AbbVie



HILDE ABRAHAMSEN ENSERINK  
Associated Head Medical Affairs  
Hematology-Oncology  
Nordic Countries  
Mobile: +47 959 46 311  
Email: [hilde.abrahamsen@abbvie.com](mailto:hilde.abrahamsen@abbvie.com)

for Roche



SAEEDA RANA  
Country Medical Manager  
Mobile: +47 913 00 938  
E-mail: [saeeda.rana@roche.com](mailto:saeeda.rana@roche.com)



abbvie

# AGENDA

11.30-12.30

## REGISTRATION & LUNCH/COFFEE

12.30-12.45

## WELCOME AND INTRODUCTION

Welcome and general outlook on MRD in CLL  
Prof. Geir Tjønnfjord and Dr. Carsten Niemann

12.45-13.30

## SESSION 1

*Chair: Geir Tjønnfjord*

MRD as a surrogate endpoint for PFS/OS in clinical trials  
Dr. Sebastian Böttcher

13.35-14.20

## SESSION 2

*Chair: Carsten Niemann*

MRD assessment in CLL and harmonization of method  
Prof. Andy Rawstron

14.20-14.40

## BREAK

14.40-16.00

## SESSION 3

*Chair: Geir Tjønnfjord*

Current practices of MDR testing in different hematological malignancies

- a) AML: Randi Hovland
- b) MCL: Dr. Arne Kolstad
- a) CLL: Dr. Carsten Niemann
- b) FL: Prof. Eva Kimby

16.05-16.15

## BREAK

16.15-17.00

## SESSION 4

*Chair: Geir Tjønnfjord*

Pros and cons of MRD in CLL: does it make sense to use MRD negativity as a therapeutic goal in hematological malignancies - are we there now?  
by Prof. Peter Hillmen and Prof. Paolo Ghia

17.00-19.00

## DINNER AND NETWORKING



DEN NORSKE  
LEGEFORENING

LMI

LEGEMIDDELINDUSTRIEN

"Dette arrangementet arrangeres i samsvar med avtaler om samhandling som Legemiddelindustriforeningen har inngått med Den norske legeforening, Norges Farmaceutiske Forening, Norsk Sykepleierforbund og De regionale helseforetakene. For deg som helsepersonell medfører dette at både du og arrangøren har rettigheter og plikter som skal sikre at arrangementet er av god faglig kvalitet og at det ikke er egnet til å skape forestillinger om uheldige bindinger mellom industri og helsepersonell. For mer informasjon se [www.lmi.no/standardinformasjon](http://www.lmi.no/standardinformasjon).